Share
1,011 Posts.
lightbulb Created with Sketch. 84
clock Created with Sketch.
14/09/14
09:09
Share
Interesting but their website does not talk of treatment candidates nor of approvals or upcoming trials. What of their products? The website focus is on recruiting.
They appear to have 2 products both preclinical.
QR-010
Column 1
Column 2
1
Company
ProQR Therapeutics B.V.
2
Description
RNA-based oligonucleotide
3
Molecular Target
4
Mechanism of Action
Antisense therapy
5
Therapeutic Modality
Nucleic acid: Linear RNA: Antisense
Column 1
Column 2
1
Latest Stage of Development
Preclinical
2
Standard Indication
Cystic fibrosis (CF)
3
Indication Details
Treat cystic fibrosis (CF)
4
Regulatory Designation
U.S. - Orphan Drug (Treat cystic fibrosis (CF));EU - Orphan Drug (Treat cystic fibrosis (CF))
5
Partner
QR-110
Did not find any patent information on this one but did find competition
http://www.thestreet.com/story/1287...gene-therapy-stocks-tackling-eye-disease.html
Column 1
Column 2
Column 3
Column 4
Column 5
Column 6
1
General Information
[/table]| ProQR Therapeutics B.V. Description| Molecular Target| Centrosomal protein 290kDa (CEP290) Mechanism of Action| Therapeutic Modality| [/table]
Column 1
Column 2
Column 3
Column 4
Column 5
Column 6
1
Latest Stage of Development
PreclinicalStandard Indication
BlindnessIndication Details
Treat Leber's congenital amaurosis (LCA)Regulatory Designation
Partner
[/table]
[/table]
It will be interesting to see how the market welcomes them.